Evidence map›Paper›PMID 40771283›Full record

SynthesisFrontiers in endocrinology2025

The expression profiles and roles of microRNAs in cardiac glucose metabolism.

Nan-Nan Shen, Hua Qian, Ya-Fang Zhu

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nan-Nan ShenDepartment of Pharmacy, Affiliated Hospital of Shaoxing University, Shao Xing, Zhejiang, China.
Hua QianDepartment of Pharmacy, Affiliated Hospital of Shaoxing University, Shao Xing, Zhejiang, China.
Ya-Fang ZhuEndoscopic center, Affiliated Hospital of Shaoxing University, Shao Xing, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: MicroRNAs (miRNAs) are a class of endogenous, non-coding RNAs, that have been implicated in cardiovascular diseases. Recent studies have suggested that dysregulated miRNAs accumulate in the heart and may be associated with impaired cardiac glucose metabolism. However an inconsistent direction of expression was observed in the current available literature. The aim of this study was to characterize miRNA expression profiles associated with glucose metabolism, and to explore their potential as biomarkers for glucose metabolism disorders in diabetic cardiomyopathy (DCM). Methods: A systematic search of electronic databases, including Embase, PubMed, and the Cochrane Library, was conducted until October 1, 2024. Studies reporting on miRNAs expression profiles that regulate glucose metabolism in the heart were selected for inclusion. Pooled results were presented as log10 odds ratios (logORs) with 95% confidence intervals (CIs), using random-effect models. Subgroup analyses were conducted based on species, region, and sample source. Analyses by species focused specifically on humans and mice. The quality of included articles was assessed using the modified Diagnostic Accuracy Study 2 (QUADAS-2) tool. All workflows, including abstract screening, full-text review, data extraction, and quality assessment, were independently performed by two reviewers. Results: A total of 47 eligible articles were included in this study, identifying 70 dysregulated miRNAs. Further analysis revealed that compared with the non-DCM group, the DCM group exhibited differential miRNA expression, with 12 miRNAs consistently upregulated and 8 consistently downregulated. Among these miRNAs, miR-199a (logOR 4.59; 95% CI: 3.02-6.15) was the most upregulated and frequently reported (n=7 studies), while let-7 (logOR 4.48; 95% CI: 2.41-6.55) was the most downregulated (4 studies). Subgroup analysis indicated that miRNA-21 was the most upregulated in cardiac tissue, and miRNA-133 was the most downregulated in cardiomyocytes. Additionally, miRNA-21 was found to be the most upregulated across different species. In the region subgroups, miRNA-199a and miRNA-503 were the most upregulated and downregulated in Asian countries, whereas miRNA-378 was the most dysregulated in non-Asian countries. Conclusion: In summary, this study identified 20 consistently dysregulated miRNAs assocaited with myocardial glucose metabolism. Six dysregulated miRNAs, including miRNA-199a, let-7, miRNA-21, miRNA-133, miRNA-503 and miRNA-378, have potential as candidate miRNA biomarkers of glycometabolism in the heart. These findings require further validation in future larger-scale studies.

Indexed as

Diabetic CardiomyopathiesGlucoseMicroRNAsMyocardiumAnimalsBiomarkersGene Expression ProfilingHumansMiceBiomarkersGlucoseMicroRNAsbiomarkerglucose metabolismheartmiRNAssystematic review

Identifiers

PMID40771283
PMCPMC12325018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.